CLPT Stock Overview
Operates as a medical device company primarily in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ClearPoint Neuro, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.55 |
| 52 Week High | US$17.47 |
| 52 Week Low | US$5.11 |
| Beta | 1.07 |
| 1 Month Change | 31.35% |
| 3 Month Change | 36.36% |
| 1 Year Change | 136.97% |
| 3 Year Change | 29.33% |
| 5 Year Change | 219.20% |
| Change since IPO | -48.18% |
Recent News & Updates
Recent updates
After Leaping 26% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar
Dec 10
Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%
Sep 14Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?
Aug 16Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 26%
Jul 11ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 09ClearPoint Neuro: Macro-Induced Multiple Compression
Apr 25Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?
Apr 19Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report
Mar 15Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?
Jan 04Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?
Dec 06Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?
Nov 06Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?
Aug 18ClearPoint Neuro, Inc. (NASDAQ:CLPT) Looks Just Right With A 40% Price Jump
Apr 17Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?
Jan 03ClearPoint Neuro: Continuous Great Execution
Sep 19ClearPoint Neuro: Picks & Shovels Galore
Aug 19ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?
Aug 18ClearPoint Neuro: A 'Picks And Shovels' Biotech Company
Jul 25ClearPoint Neuro: Continuous Execution Despite Covid Headwind
May 20Shareholder Returns
| CLPT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -3.9% | -1.2% | -2.7% |
| 1Y | 137.0% | 10.0% | 23.4% |
Return vs Industry: CLPT exceeded the US Medical Equipment industry which returned 10% over the past year.
Return vs Market: CLPT exceeded the US Market which returned 23.4% over the past year.
Price Volatility
| CLPT volatility | |
|---|---|
| CLPT Average Weekly Movement | 10.0% |
| Medical Equipment Industry Average Movement | 7.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CLPT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CLPT's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 107 | Joe Burnett | www.clearpointneuro.com |
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.
ClearPoint Neuro, Inc. Fundamentals Summary
| CLPT fundamental statistics | |
|---|---|
| Market cap | US$428.80m |
| Earnings (TTM) | -US$18.15m |
| Revenue (TTM) | US$30.43m |
14.1x
P/S Ratio-23.6x
P/E RatioIs CLPT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLPT income statement (TTM) | |
|---|---|
| Revenue | US$30.43m |
| Cost of Revenue | US$12.06m |
| Gross Profit | US$18.37m |
| Other Expenses | US$36.52m |
| Earnings | -US$18.15m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.66 |
| Gross Margin | 60.38% |
| Net Profit Margin | -59.64% |
| Debt/Equity Ratio | 0% |
How did CLPT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 04:43 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ClearPoint Neuro, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| Kyle Bauser | B. Riley Securities, Inc. |
| Sally Yanchus | Brookline Capital Markets |